Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 1

Interventions

Cyclophosphamide 31Rituximab 26Biopsy 23Specimen Handling 21Magnetic Resonance Spectroscopy 18fludarabine 14Prednisone 14Vincristine 11Doxorubicin 11obinutuzumab 10Lenalidomide 10Etoposide 10Bendamustine Hydrochloride 9pembrolizumab 7venetoclax 6fludarabine phosphate 6X-Rays 6Tacrolimus 6Nuclear Medicine Department, Hospital 6Dexamethasone 6Bortezomib 6trametinib 5ibrutinib 5glofitamab 5acalabrutinib 5Nivolumab 5Mycophenolic Acid 5Gemcitabine 5Crizotinib 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × eflapegrastim × 90 days × Clear all
NCT04570423 2026-05-22

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Spectrum Pharmaceuticals, Inc

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡